Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 8, 2009, Pages 1417-1423

  Han, Yue ^a   Huang, Li Hua ^b   Liu, Chuan Miao ^c   Yang, Shu ^d   Li, Juan ^e   Lin, Zhi Mei ^a   Kong, Xiao Fei ^a   Yu, De Min ^a   Zhang, Dong Hua ^a   Jin, Gen Di ^a   Lu, Zhi Meng ^a   Gong, Qi Ming ^a   Zhang, Xin Xin ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Wu Xi Infectious Diseases Hospital   (China)

^c No 1 Hospital   (China)

^d Department of Infectious Diseases   (China)

^e JILIN UNIVERSITY   (China)

Author keywords

Deep sequence analysis; Hepatitis B virus; Mutant; Reverse transcriptase; Treatment naive

Indexed keywords

DINUCLEOTIDE; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE; THYMIDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; DATA BASE; FEMALE; GENE AMPLIFICATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS CHARACTERIZATION; VIRUS STRAIN;

EID: 69049086720     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05864.x     Document Type: Article

References (25)

1. Wang Z, Huang Y, Wen S, Zhou B, Hou J. Hepatitis B virus genotypes and subgenotypes in China. Hepatol. Res. 2007 37 (Suppl. 1) S36 41.
2. Norder H, Couroucé AM, Coursaget P et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004 47 : 289 309.
3. Wang Z, Huang Y, Wen S, Zhou B, Hou J. Hepatitis B virus genotypes and subgenotypes in China. Hepatol. Res. 2007 37 (Suppl. 1) S36 41.
4. Wang Z, Hou J, Zeng G et al. Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China. J. Viral. Hepat. 2007 14 : 426 434.
5. Zeng G, Wang Z, Wen S et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J. Viral. Hepat. 2005 12 : 609 617.
6. Leung N. Chronic hepatitis B - treatment with nucleoside analogues. Med. J. Malaysia 2005 60 (Suppl. B) 22 7.
7. Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Hepatobiliary Pancreat. Dis. Int. 2004 3 : 188 193.
8. Billich A. Entecavir (Bristol-Myers Squibb). Curr. Opin. Investig. Drugs 2001 2 : 617 621.
9. Hache C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin. Pharmacother. 2006 7 : 1835 1843.
10. Hache C, Villeneuve JP. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. Expert Opin. Pharmacother. 2006 7 : 1835 1843.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005 (Jun 30) 352 (26) 2673 2681.
12. Rivkin A. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. Drugs Today (Barc). 2007 43 : 201 220.
13. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief. Bioinform. 2004 5 : 150 163.
14. Xia X, Xie Z. DAMBE: software package for data analysis in molecular biology and evolution. J. Hered. 2001 92 : 371 373.
15. Walther D, Bartha G, Morris M. Basecalling with LifeTrace. Genome Res. 2001 11 : 875 888.
16. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, Arias A. Viruses as quasispecies: biological implications. Curr. Top. Microbiol. Immunol. 2006 299 : 51 82.
17. Jenkins GM, Pagel M, Gould EA, de A Zanotto PM, Holmes EC. Evolution of base composition and codon usage bias in the genus Flavivirus. J. Mol. Evol. 2001 52 : 383 390.
18. Argos P, Rossmann MG, Grau UM, Zuber H, Frank G, Tratschin JD. Thermal stability and protein structure. UCLA Forum Med. Sci. 1979 21 : 159 169.
19. van Hemert FJ, Berkhout B. The tendency of lentiviral open reading frames to become A-rich: constraints imposed by viral genome organization and cellular tRNA availability. J. Mol. Evol. 1995 41 : 132 140.
20. Paik YH, Han KH, Hong SP et al. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. Antivir. Ther. 2006 11 : 447 455.
21. Zhang X, Liu C, Gong Q et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J. Gastroenterol. Hepatol. 2003 18 : 1353 1357.
22. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J. Viral. Hepat. 1997 4 (Suppl. 1) 11 20.
23. Chang MH Hepatitis B virus mutation in children. Indian J. Pediatr. 2006 73 : 803 807.
24. von WF, Pult I, Geiss K, Wirth S, Blum HE. Selective transmission of variant genomes from mother to infant in neonatal fulminant hepatitis B. Hepatology 1995 21 : 8 13.
25. Metzner KJ, Rauch P, Walter H et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005 (Nov 4) 19 (16) 1819 1825.